1. The overall objective is to assess a seasonal preventive strategy targeting school-aged children in Mali, using either Dihydroartemisinin and Piperaquine (DHA-PQ), SP-AQ or control.
A double blind randomized controlled clinical trial to assess the efficacy of Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine associated to Amodiaquine for Seasonal Malaria Chemoprevention in school children aged from 6-15 years in Mali, 3 treatments arms. Four SMC rounds were conducted
School aged children (6-15 years old at Bandiagara, Mali
Incidence of clinical malaria and prevalence of malaria infection by treatment arms; Incidence of adverse events reported following administration of study drugs by treatment arms; Prevalence of malaria parasitaemia (sexual and asexual forms) at monthly visits by treatment arms: Prevalence of anemia; Prevalence of resistance markers to artemisinin and Piperaquine in children carrying parasites at the end of malaria transmission seasons; Dynamics of children performance at schools during the study period; Parasite genetic diversity.
The trial has been completed in September 2021; the last participant last visit occurred on September 21st, 2021. The trial results have been successively presented at EDCTP tenth meeting, the congress of the African Society of Parasitology, and an abstract is submitted and accepted as poster presentation to the ASTMH meeting. Overall, DHA-PQ and SP-AQ showed a good tolerability and high efficacy in SMC in school-aged children. The analysis of data and samples are ongoing in the laboratories to address other endpoints.
EDCTP Clinical Research & Development Fellowship